ClinicalTrials.gg
RecruitingNCT06315192StrokeAlarmEFFUpdated Jun 30, 2026

Stroke Alarm Efficacy Trial

An interventional study of Stroke Alarm in Stroke Acute, Atrial Fibrillation and TIA, sponsored by Region Skane. Recruiting at 10 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Region Skane · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 158 studies in Stroke with a site in Sweden — 30 open to participants now, 42 under way, 5 of them phase 3. Stroke · Sweden.

Planned enrollment
49th of 123
500 · median 200
Started
2024
with 1 other
No phase
74 of 158
18 open now
Primary completion
2027-10
later than 24 of 41 live
Registered
134th of 158
by date
Lead sponsor
9 of 158
Region Skane

Among the 158 studies in Stroke with a site in Sweden, this one is the 49th largest by planned enrollment of the 123 interventional ones that give a count, is one of 2 that started in 2024, is one of 74 with no phase, reaches primary completion later than 24 of the 41 other live ones, and was the 134th registered.

Stroke

8,281 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

30 of the 158 studies in Stroke with a site in Sweden are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Stroke with a site in Sweden, or all of them as a file.
02

Study summary

The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.

This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.

A total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.

Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.

Patients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:

  1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR
  2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR
  3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR
  4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.

A control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a/5b 1-4), presence of neglect/inattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.

Read the detailed description

Objectives and hypotheses of the clinical investigation The aim of this study is to test the ability and efficacy of the CE-marked wearable system Stroke Alarm to detect a stroke onset early.

The hypothesis is that the Stroke Alarm is able to indicate at least 60% of stroke cases with unilateral arm motor deficit within 3 hours of onset with a specificity of at least 80%.

Design of the clinical investigation This is a prospective single arm observational trial with a propensity-matched registry-derived control group.

All patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits, TIA or atrial fibrillation at the participating hospitals that fulfill all inclusion critera and no exclusion criteria is asked for participation in the trial.

The patient is after the setup wearing the device continuously for three months.

An administrative follow-up is performed at 90-120 days following inclusion, the EPR is reviewed for any hospital admissions for stroke during the study period.

No standard care comparator will be used in this study, mainly because of lack of similar systems to compare with and blinding issues.

Simultaneous inclusion in other studies that require bracelets are not permitted, but inclusion in other clinical treatment trials, such as for drugs och medical devices that does not require bracelets, are acceptable.

Study population All patients (age ≥ 50 years) with a recent diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits or TIA at the participating hospitals are candidates for participation in the trial. Patients have to be at increased risk for stroke, defined by ABCD2 score of ≥6 (TIA), presence of large artery atherosclerosis or atrial fibrillation (TIA and/or ischemic stroke), or atrial fibrillation (intracerebral hemorrhage). Patients with atrial fibrillation without adequate anticoagulation and a CHA2DS2-VAsc score ≥ 4 can be included at any time point.

Enrollment Patients with a diagnosis of stroke (ischemic stroke or intracerebral hemorrhage) without arm motor deficits, TIA or atrial fibrillation that fullfill all inclusion and have no exclusion criteria are included after signing the informed consent form at inclusion visit after oral and written information within the hospital or at an out-patient facility (described in Informed consent process, section 16).

Included subjects are added to the identification log stored in the Investigators Site File (ISF) that is located in locked research offices at the participating hospitals. The Identification log is under no circumstances shared or moved from the ISF that is located at participating hospital.

The patients are instructed to use the device continuously for three months. When setting-up the app on their smartphones they will be required to add at least one alarm recipient, but adding more alarm recipients is encouraged. The recipients are independent of study design and can be family members, friends or neighbors, as preferred by the subjects.

Device startup The study nurses manage the inclusion procedure that are recorded in the EPR and the administrative system according to the local regulations of the including center.

The wearable stroke indication system is given to the patient when accepting inclusion in the trial. The system will include a user manual with step-by-step instructions that are used during the activation of the investigational device, Stroke Alarm. The Study nurse may also assist in activation, including adding alarm recipients which is exactly the same as expected during clinical routine use.

The product is designed for continuous use for up to 6 months in a home environment and can also be used in a hospital environment. The devices will not be re-used for another subject and collected by the manufacturer at the end of the study.

The device is not MR-compatible. The included patient is the user of the device. Each participant will receive one unit of Stroke Alarm, consisting of a pair of sensor bracelets and one IFU. The smartphone app is downloaded from Apple's AppStore (iOS) or via Google Play (Android). Other operative systems can't be used.

The device is intended to be used continuously during the entire study period of 90 days. During the study the user is instructed to use the device according to the IFU. The user is instructed to use the device in his/her regular activities in the home environment continuously during the entire study period.

For the device to be fully functional, the user needs to activate and wear both sensor bracelets, install the Stroke Alarm app, complete the on-boarding and have at least one alarm recipient who has accepted the invitation to act as alarm recipient. Also, for the device to be fully functional, the user needs to be within Bluetooth connection from his/her smartphone, the smartphone needs to be active and have wifi- or 3G/4G/5G internet access.

At startup, the user invites Alarm recipients, who will be alerted via SMS messages in case the device indicates stroke by identifying arm motor deficiency that may be consistent with stroke and the initial indication is not abolished by the user. Any number of Alarm recipients can be chosen, typically they may be relatives, neighbors and friends. An Alarm recipient is not registered to the system unless he/she accepts his/her role as an Alarm recipient for the user. At least one confirmed Alarm recipient is necessary for the system to be operational. Alarm recipients can be added or removed during the study period. The choice of, and role for the Alarm recipients is identical in the study as in regular use. That means that the user will select Alarm recipients based on his/her own preferences and they are supposed to react to any alarms from the device as they would to the device in regular use. An Alarm recipient is not a study subject, and no informed consent is obtained. The identity of the Alarm recipients is not collected in the study.

During setup are the user testing the stroke test (Appendix A) that consists of 8 questions/tasks designed to mimic the items tested by the NIHSS and the different types of sound and/or vibration alarms (described bellow) for better understanding of the differences between them.

Similar to regular use of the device, the study subjects may contact the manufacturer's support-service for questions and support related to the device.

Alarm description A false indication is an indication made by the algorithm from imbalance of arm activity in the absence of a stroke. It can occur during everyday activity dominated by one arm. It will lead to a false alarm if it is not abolished by user tests.

Dedicated arm motion (Escalation step 1, Figure 2) is a specified gesture (draw a ball in the air) that is used to identify erroneous indications.

In-app test (Escalation step 2, Figure 2) is the test included in the Stroke Alarm smartphone app intended to abolish erroneous indications that are not eliminated by a dedicated arm motion (Escalation step 1).

A false alarm is a SMS alarm sent to the Alarm recipients based on an initial false indication made by the algorithm in the absence of a stroke with unilateral arm motor defecit.

SMS messages to the Alarm recipients generated by technical problems that affect the function of the device (for example loss of internet-connection or loss of Bluetooth-connection) is not considered false alarms.

If the user suffers a stroke and is not able to alert himself/herself and an arm paresis associated with the stroke is detected by the device, this will first generate a true indication manifested as vibration in the bracelet of the affected arm. If the user does not abolish this indication by a dedication arm movement, it will trigger a local alarm in the smartphone within 30 seconds. If the user does not open the smartphone app and complete the in-app stroke test within 10 minutes a SMS alarm is sent to all Alarm recipients. Alarm recipients are then expected to promptly act to ensure that the user is either confirmed to be well or is taken care of by healthcare, similar as if the user had called for help by any other means.

If the user suffers a stroke with unilateral arm weakness, and is unable to alert himself/herself and no arm paresis is detected by the device (false negative) the device has not contributed to patient care and stroke diagnosis, similar to if the device not was present. In this case the workflow is the same as without the device; which means that the patient will need to alert healthcare himself/herself, of by help of others who may be present at onset or who may discover the patient at a later timepoint.

The device does not contact health care services. This contact must be initiated by the user or by Alarm recipients alerted by the device or other means.

03

Conditions studied

  • Stroke Acute
  • Atrial Fibrillation
  • TIA

Keywords

  • Stroke
  • wearable
  • indication
  • sensor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 50 years or older
  2. Modified Rankin scale of 0-2.
  3. Diagnosed with either:

    A. Recent* (TIA, G45.9), AND:

    • ABCD2 score of ≥6, OR:
    • Atrial fibrillation OR:
    • Large artery atherosclerosis**.

    B. Recent* acute ischemic stroke (I63), AND:

    • Atrial fibrillation, OR:
    • Large artery atherosclerosis**. C. Atrial fibrillation/flutter (I48), AND
    • None, or reduced dose of, oral anticoagulation medication***, AND
    • CHA2DS2-VASC score ≥4.

    D. Recent* intracerebral hemorrhage (I61.9), AND:

    • Atrial fibrillation.
  4. The patient has received the required information about the study and agrees in writing to participate.
  5. Smartphone user since at least 1 year.

    • Within the last 2 weeks **Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.

      • Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.

Exclusion criteria

EXCLUSION CRITERIA

  1. Previous inclusion in this study.
  2. Arm motor deficit from any previous medical condition.
  3. Unable to give to participate in the study.
  4. Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.
  5. Does not have access to a Stroke Alarm compatible smartphone.
  6. Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.
  7. Does not want to participate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Stroke Alarm use

    The patients are provided with Stroke Alarm and instructed to use it in accordance with the IFU for a 3 months period.

    Device: Stroke Alarm

Interventions

  • DeviceStroke Alarm

    Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.

06

What researchers measure

Primary outcomes

  1. Alarm from device within 3 hours of onset of stroke with unilateral arm motor deficit.

    The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

    Time frame: From enrollment to the end of treatment at 3 months

Secondary outcomes

  1. Time from onset of stroke with unilateral arm motor deficit until alarm by device.

    2\. Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.

    Time frame: From enrollment to the end of treatment at 3 months

  2. Time from onset of stroke with unilateral arm motor deficit until arrival to first hospital.

    The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

    Time frame: From enrollment to the end of treatment at 3 months.

  3. Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of stroke.

    The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

    Time frame: From enrollment to the end of treatment at 3 months.

  4. Number of alarms indicated by the device within 3 hours of onset, in patients with a subsequent clinical diagnosis of a stroke mimic.

    The alarm is recorded systematically from the device backend. The ground truth is gathered based on the medical records for stroke events during the study period.

    Time frame: From enrollment to the end of treatment at 3 months.

  5. Number of IVT and/or EVT treatments.

    Number of IVT and/or EVT treatments during the study period.

    Time frame: From enrollment to the end of treatment at 3 months

  6. Number of complications/adverse events generated by the device.

    Any complications/adverse events generated by the device during the study period.

    Time frame: From enrollment to the end of treatment at 3 months

Other outcomes

  1. Number of false alarms

    False alarms generated by the device.

    Time frame: From enrollment to the end of treatment at 3 months

  2. Number of patients with missed strokes

    Clinically diagnosed stroke events with unilateral arm paresis.

    Time frame: From enrollment to the end of treatment at 3 months

  3. Number of patients dying during the study period.

    Death for any reason.

    Time frame: From enrollment to the end of treatment at 3 months

  4. Number of device-related events.

    Adverse events related to the device.

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 37 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 37 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Mar 18, 2024
StartActual
Sep 5, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06315192
Lead sponsor
Region Skane
Collaborators
Karolinska University Hospital, Stockholm South General Hospital, Sahlgrenska University Hospital, Skane University Hospital, Hässleholm Hospital, Uppsala University Hospital, Helsingborgs Hospital, University Hospital, Linkoeping
Responsible party
Sponsor
First posted
Mar 18, 2024
Start date
Sep 5, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Magnus Esbjörnsson, MD
Contact
magnus.esbjornsson@skane.se
800-555-5555 ext. 46-451-298753
Johan Wasselius, MD, PhD
Contact
johan.wasselius@gmail.com
800-555-5555 ext. 46-46-173082
Ulrika Anderson, Ms.
study director · Lund University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion